TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03708094

Intervention type: DIAGNOSTIC_TEST
Intervention: molecular diagnosis
Description: whole exome sequencing and data analysis to elucidating molecular diagnosis
Study: NCT01956474

Intervention type: OTHER
Group type: OTHER
Intervention: Theralight crosslinking and Riboflavin
Description: Corneal Collagen cross linking with UV light and riboflavin
Study: NCT02625610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Induction Phase: 5-Fluorouracil was administered at a dose of 2600 mg/m\^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m\^2 IV push on Day 1 and 2400 mg/m\^2 IV continuous infusion over 46-48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks. Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Induction Phase: Leucovorin was administered at a dose of 200 mg/m\^2 IV (or) Leucovorin 400 mg/m\^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.
Study: NCT02286232

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stretching exercise
Description: This program begins with 10 stretches/exercises over 15 minutes on the initial class and incrementally increases by 1 stretch/exercise each session for a total of 21 stretches/exercises over 30 minutes on the 12th session. The program is designed to stretch/exercise the major muscle groups, emphasizing the neck and arms, trunk, and legs. In addition to the stretches, each class will include breathing exercises and guided imagery for relaxation. Classes will be taught by Physical Therapists who are trained to lead classes through the protocol.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-care book
Description: The Back Pain Helpbook which provides information on the causes of back pain and advice on exercising, making appropriate lifestyle modifications, and managing flare-ups.
Study: NCT01402739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Point of Care Coagulation Monitoring Guided Transfusion Algorithm
Description: (thromboelastometry, aggregometry, blood gas analysis)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard coagulation monitoring guided transfusion algorithm
Description: aPTT, ACT, platelet count, hemoglobin, fibrinogen
Study: NCT01248949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3617
Description: Participants will receive MEDI3617 via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.
Study: NCT03326011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Samsung Hip Assist v1
Description: All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions. Each session is directed by a licensed physical therapist and lasted 60 min including rest period of 10 min. Brain activity and gait assessment is performed at visits 0 (baseline), 24 (post-test), and at 3 months (follow-up) after training.
Study: NCT06032312

Intervention type: OTHER
Intervention: description
Description: no intervention, just description of the groups
Study: NCT00678210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: tablets, 2 mg BID for 12 weeks
Study: NCT00678210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: tablets, 5 mg BID for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: tablets, 15 mg BID for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets, BID for 12 weeks
Study: NCT01248949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3617
Description: Participants will receive MEDI3617 via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3617
Description: Participants will receive MEDI3617 via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3617
Description: Participants will receive MEDI3617 via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participants will receive bevacizumab via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Participants will receive bevacizumab via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Participants will receive paclitaxel via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Participants will receive paclitaxel via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants will receive carboplatin via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons.
Study: NCT01128946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaF
Description: Fluoride toothpaste containing sodium fluoride as 1450 parts per million (ppm) F, 675 ppmF, 450 ppmF, 350ppmF.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaF
Description: Fluoride toothpaste containing sodium fluoride as 1450 parts per million (ppm) F, 675 ppmF, 450 ppmF, 350ppmF.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaF
Description: Fluoride toothpaste containing sodium fluoride as 1450 parts per million (ppm) F, 675 ppmF, 450 ppmF, 350ppmF.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NaF
Description: Fluoride toothpaste containing sodium fluoride as 1450 parts per million (ppm) F, 675 ppmF, 450 ppmF, 350ppmF.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SnF
Description: Fluoride toothpaste containing stannous fluoride (1100 ppmF)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaMFP
Description: Fluoride toothpaste containing sodium monofluorophosphate (1000 ppmF)
Study: NCT03998969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Pantoprazole 40mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Pantoprazole 40mg tablet
Study: NCT01838642

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ponatinib
Description: Ponatinib tablets will be administered orally, continually, once daily at a dose of 30 mg. A cycle of ponatinib is defined as 28 consecutive days starting with the first day of the treatment cycle. Treatment will be administered primarily in an outpatient setting.
Study: NCT03998969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-5204
Description: DA-5204 tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet manufactured to mimic DA-5204
Study: NCT03941626

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T/TCR-T cells immunotherapy
Description: According to tumor burden and other conditions, patients will be treated with cyclophosphamide or fludarabine,then,CAR-T cells will be infused 48-72 hours later.
Study: NCT01339897

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 mg/N6022
Description: Intravenous formulation, given at doses of 5 mg once each day over 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same administration procedures as active

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10mg/N6022
Description: Intravenous formulation given at doses of 10 mg once each day over 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20mg/N6022
Description: Intravenous formulation given at doses of 20 mg once each day over 7 days.
Study: NCT01884272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lesinurad 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lesinurad 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naproxen 250 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: indomethacin 25 mg
Study: NCT04569981

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Climbing
Description: The patients in the Climbing Group (CG) followed a 12-weeks long climbing trainings course in small groups of 3-4 participants with a certified climbing instructor.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Unsupervised activity group
Description: The patients in the unsupervised activity group (UAG) received education European physiotherapy guidelines for physical activity recommended by the WHO of recommended activity and followed their self-selected activities over 12 weeks.
Study: NCT00862056

Intervention type: PROCEDURE
Intervention: Cardiac CT
Description: All participants will undergo a coronary artery CT angiogram with contrast.
Study: NCT03245775

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iChoose
Description: 12 bi-weekly sessions \& 24 IVR calls/12 months, 24 physical activity sessions over 6 months; delivers intervention to parents and children only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Connections
Description: 2 in-person sessions spaced one week apart \& 10 IVR calls/6 months, promotes physical activity but does not include structured exercise sessions; delivers intervention to parents only
Study: NCT00406679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol (acetaminophen) solution experimental
Description: 1 gm IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol (acetaminophen) solution commercial
Description: 1 gm IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: equivalent volume IV 0.9% sodium chloride (equivalent volume)
Study: NCT03821610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melphalan
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alemtuzumab
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (8Gy)
Description: TBI (8Gy)
Study: NCT00766051

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The intervention group: Neurophysiologically Based Occupational Therapy Intervention (NBOTI)
Description: This study included a pre-feeding, feeding, and postural-respiratory protocol, given per the attending physician's order. The interventions were given daily when possible, and the infants FiO2 and heart rate, along with stress behaviors, were monitored prior to, during, and after the NBOTI. The intervention included parent education for feeding, handling, and interaction with their infant, along with nursing training during the feeding session. The occupational therapy investigator partnered with the parents and when the parents were not available, she partnered with the nursing staff.
Study: NCT04152408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FiberSense System
Description: FiberSense system, a novel CGM system, based on a fiber-optical sensor placed through the dermis of the patient.
Study: NCT02625610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Induction Phase: Capecitabine was administered at a dose of 1000 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.~Maintenance Phase: Participants were continued the same regimen of chemotherapy as they received during the Induction Phase every 3 weeks until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best supportive care
Description: Treatment administered with the intent to maximize Quality of Life (QoL) without a specific antineoplastic regimen. These may include for example antibiotics, analgesics, antiemetics, thoracentesis, paracentesis, blood transfusions, nutritional support (including jejunostomy), and focal external-beam radiation for control of pain, cough, dyspnea, or bleeding. Best supportive care were administered per institutional guidelines and participants were visit the clinic every 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Induction Phase: Oxaliplatin will be administered at a dose of 85 mg per square meter (mg/m\^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m\^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Induction Phase: 5-Fluorouracil will be administered at a dose of 2600 mg/m\^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m\^2 IV push on Day 1 and 2400 mg/m\^2 IV continuous infusion over 46-48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Induction Phase: Leucovorin will be administered at a dose of 200 mg/m\^2 IV (or) Leucovorin 400 mg/m\^2 IV on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.
Study: NCT01839812

Intervention type: DRUG
Group type: OTHER
Intervention: Cosyntropin
Description: A cosyntropin stimulation test is administered to each patient at 3 time points during the study to evaluate adrenal response.
Study: NCT03302247

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Monoclonal antibody against non small cell lung cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab+Gemcitabine
Description: Gemcitabine is added to the Nivolumab treatment
Study: NCT03062111

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ProTouch Laser Enucleation of Prostate (LEP)
Description: Laser enucleation of the prostate is a standard form of treatment for BPH used widely. The ProTouch laser is established to be safe and is newer than the holmium laser.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral Resection of Prostate (TURP)
Description: TURP has been considered a gold standard for treatment of BPH in which rigid resectoscopes with bipolar cautery are used to endoscopically resect prostatic tissue.
Study: NCT02371603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863 25 mg Tablet
Description: A round, biconvex, white film coated tablet to be taken orally in the fasted state in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1278863 25 mg Tablet
Description: A round, biconvex, white film coated tablet to be taken orally in the fasted state in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg Tablet
Description: White to off-white, round, convex, non scored tablet with ACTOS on one side, and 15 on the other, to be taken orally in the fasted state in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg Tablet
Description: Pink, round, biconvex, coated tablets. Debossed CRESTOR and 10 on one side, to be taken orally in the fasted state in the morning
Study: NCT03127891

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pranayama yoga
Description: providing short term pranayama yoga for 5 sessions before surgery patients under going cardiac surgery.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: no intervention should be given to patients allocated to this group
Study: NCT04010721

Intervention type: DEVICE
Group type: OTHER
Intervention: Experiment 1
Description: Stimulation of one electrode at a time

Intervention type: DEVICE
Group type: OTHER
Intervention: Experiment 2:
Description: Stimulation in groups of 4, 8 and 12 electrodes
Study: NCT02625610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Induction Phase: Capecitabine will be administered at a dose of 1000 mg/m\^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.
Study: NCT03089229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAT01H Cream
Description: HAT01H Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Vehicle Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
Study: NCT00389909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxapram
Description: Dosing comparison between fixed scheduled and sex related dosage.~Dosing related to weight only versus chart taking into account weight, age and gender.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxapram
Description: Dosing comparison between fixed scheduled and sex related dosage.~Dosing related to weight only versus chart taking into account weight, age and gender.
Study: NCT02789761

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-flavanol milk choocolate

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low-flavanol milk chocolate
Study: NCT03458351

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic preconditioning
Description: Four cycles of 5 min of ischemia, which is induced by a blood pressure cuff in the upper arm inflated to 200 mmHg, followed by 5 min of reperfusion, during which the cuff is deflated.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham control
Description: The same blood pressure cuff is placed around the upper arm, but the cuff is inflated to 10 mm Hg and ischemic preconditioning is not induced.
Study: NCT03622294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bella Blankets protective coverlets
Description: Bella Blankets protective coverlets is a Class II 510(k) Cleared (2008) single-use, adhering, non-woven fabric sheet applied to the mammography equipment receptor plate to provide a more comfortable mammogram.
Study: NCT04257656

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: RDV 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Remdesivir placebo
Description: RDV placebo 200 mg loading dose on day 1 is given, followed by 100 mg iv once-daily maintenance doses for 9 days.
Study: NCT01494909

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ensure plus
Description: Ensure plus sip feeds every 20 min during 6 hours. After 2 hour pancreatic enzyme intake in CF
Study: NCT02746276

Intervention type: DRUG
Group type: OTHER
Intervention: Ceftriaxone
Description: Ceftriaxone is active against a broad spectrum of gram positive and gram negative bacteria, including intracellular bacteria (e.g. Salmonellae, Staphylococci). Its antibacterial effect is dependent on time above the minimum inhibitory concentration(MIC). Ceftriaxone is highly protein-bound and elimination depends on glomerular filtration rate. In severely ill adults, elimination is highly variable. Alteration in plasma proteins, volume of distribution and renal function in sick severely malnourished children could significantly alter pharmacokinetics (PK). Despite several published studies on the PK of ceftriaxone in children, none have included severe malnutrition.
Study: NCT02371603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim 100 mg Tablet
Description: White, round, scored, convex tablet, debossed 93 above the score and debossed 2159 below the score on one side and plain on the other, to be taken orally as two tablets once in the morning and once in the evening
Study: NCT00665548

Intervention type: RADIATION
Intervention: X-ray; magnetic resonance imaging
Description: Knee x-rays: acquired in both a standard or weight-bearing position and in non-weight-bearing position to measure joint space width and look at signs of osteoarthritis.~3 Tesla MRI: magnetic resonance imaging of the study knee during weight-bearing conditions and traditional non-loaded condition all acquired with the same sequences.
Study: NCT01152372

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Insulin, glucose and staple isotopes

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Insulin, glucose and staple isotopes
Study: NCT01152372

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Insulin, glucose and staple isotopes
Study: NCT02571699

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subgluteal Nerve Block
Description: ultrasound-guided subgluteal sciatic nerve block.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Subgluteal Nerve Block
Description: ultrasound-guided subgluteal sciatic nerve block.
Study: NCT00055731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bicalutamide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bicalutamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin Acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel